Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Apr 23

PMID 35456712

Authors

Juan Eduardo Megias-Vericat

David Martinez-Cuadron

Antonio Solana-Altabella

Jose Luis Poveda

Pau Montesinos

Affiliations

Soon will be listed here.

Abstract

Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette family (ABC) pumps. Genetic variability in and could produce interindividual differences in clinical outcomes. A systematic review was performed to evaluate the influence of and polymorphisms and their combinations on efficacy and safety in AML cohorts. Anthracycline intake was especially influenced by polymorphisms, associated with lower hepatic uptake, showing higher survival rates and toxicity in AML studies. The variant alleles of were related to anthracycline intracellular accumulation, increasing complete remission, survival and toxicity. Similar findings have been suggested with and polymorphisms. Polymorphisms of , responsible for cytarabine uptake, demonstrated significant associations with survival and response in Asian populations. Promising results were observed with and combinations regarding anthracycline toxicities. Knowledge of the role of transporter pharmacogenetics could explain the differences observed in drug disposition in the blast. Further studies including novel targeted therapies should be performed to determine the influence of genetic variability to individualize chemotherapy schemes.

Citing Articles

Can pharmacogenetics impact the therapeutic effect of cytarabine and anthracyclines in adult acute myeloid leukaemia patients?: A Serbian experience.

Pravdic Z, Suvajdzic-Vukovic N, Virijevic M, Mitrovic M, Pantic N, Sabljic N J Med Biochem. 2024; 43(4):545-555.

PMID: 39139169 PMC: 11318899. DOI: 10.5937/jomb0-47459.

Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.

Marrero R, Wu H, Cao X, Parcha P, H Elsayed A, Inaba H Clin Cancer Res. 2024; 30(19):4388-4396.

PMID: 39078289 PMC: 11444877. DOI: 10.1158/1078-0432.CCR-24-0863.

Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.

Cereja-Pantoja K, de Brito Azevedo T, Vinagre L, de Moraes F, da Costa Nunes G, Monte N Cancer Chemother Pharmacol. 2024; 94(3):387-395.

PMID: 38888766 DOI: 10.1007/s00280-024-04689-x.

Metabolomics and proteomics analyses revealed mechanistic insights on the antimicrobial activity of epigallocatechin gallate against .

Gao T, Ye F, Tan Y, Peng M, Yuan F, Liu Z Front Cell Infect Microbiol. 2022; 12:973282.

PMID: 36204637 PMC: 9531131. DOI: 10.3389/fcimb.2022.973282.

References

Parmar S, Seeringer A, Denich D, Gartner F, Pitterle K, Syrovets T . Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics. 2011; 12(4):503-14. DOI: 10.2217/pgs.10.200. View

Zhang J, Visser F, King K, Baldwin S, Young J, Cass C . The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 2007; 26(1):85-110. DOI: 10.1007/s10555-007-9044-4. View

Yee S, Mefford J, Singh N, Percival M, Stecula A, Yang K . Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013; 58(6):353-61. PMC: 4068832. DOI: 10.1038/jhg.2013.38. View

Rafiee R, Chauhan L, Alonzo T, Wang Y, Elmasry A, Loken M . ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer J. 2019; 9(6):51. PMC: 6529443. DOI: 10.1038/s41408-019-0211-y. View

Benderra Z, Faussat A, Sayada L, Perrot J, Chaoui D, Marie J . Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004; 10(23):7896-902. DOI: 10.1158/1078-0432.CCR-04-0795. View

Roumier C, Cheok M . Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics. 2009; 10(11):1839-51. DOI: 10.2217/pgs.09.130. View

Hertz D, Caram M, Kidwell K, Thibert J, Gersch C, Seewald N . Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016; 17(3):231-40. PMC: 5558515. DOI: 10.2217/pgs.15.162. View

Ross D, Karp J, Chen T, Doyle L . Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000; 96(1):365-8. View

Illmer T, Schuler U, Thiede C, Schwarz U, Kim R, Gotthard S . MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002; 62(17):4955-62. View

10.

Mahjoubi F, Akbari S, Montazeri M, Moshyri F . MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients. Genet Mol Res. 2008; 7(4):1369-74. DOI: 10.4238/vol7-4gmr482. View

11.

Megias-Vericat J, Montesinos P, Herrero M, Moscardo F, Boso V, Rojas L . Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2016; 58(5):1197-1206. DOI: 10.1080/10428194.2016.1231405. View

12.

Osato D, Huang C, Kawamoto M, Johns S, Stryke D, Wang J . Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics. 2003; 13(5):297-301. DOI: 10.1097/00008571-200305000-00010. View

13.

Megias-Vericat J, Martinez-Cuadron D, Herrero M, Rodriguez-Veiga R, Solana-Altabella A, Boluda B . Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2020; 62(3):659-668. DOI: 10.1080/10428194.2020.1839650. View

14.

Lane H, Tsai G, Lin E . Assessing gene-gene interactions in pharmacogenomics. Mol Diagn Ther. 2012; 16(1):15-27. DOI: 10.1007/BF03256426. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

16.

Tiribelli M, Geromin A, Michelutti A, Cavallin M, Pianta A, Fabbro D . Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer. 2011; 117(10):2156-62. DOI: 10.1002/cncr.25753. View

17.

Varatharajan S, Abraham A, Karathedath S, Ganesan S, Lakshmi K, Arthur N . ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. Pharmacogenomics. 2017; 18(3):235-244. DOI: 10.2217/pgs-2016-0150. View

18.

Yee S, Giacomini K . . Drug Metab Dispos. 2021; 50(9). PMC: 9488978. DOI: 10.1124/dmd.121.000702. View

19.

Vulsteke C, Pfeil A, Maggen C, Schwenkglenks M, Pettengell R, Szucs T . Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat. 2015; 152(1):67-76. DOI: 10.1007/s10549-015-3437-9. View

20.

Peters B, Rodin A, Klungel O, Van Duijn C, Stricker B, Vant Slot R . Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics. 2010; 11(8):1065-76. DOI: 10.2217/pgs.10.81. View